MX2023002024A - Métodos de tratamiento con modulador de miosina. - Google Patents

Métodos de tratamiento con modulador de miosina.

Info

Publication number
MX2023002024A
MX2023002024A MX2023002024A MX2023002024A MX2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A MX 2023002024 A MX2023002024 A MX 2023002024A
Authority
MX
Mexico
Prior art keywords
treatment
methods
myosin
modulator
myosin modulator
Prior art date
Application number
MX2023002024A
Other languages
English (en)
Spanish (es)
Inventor
Jay M Edelberg
Amy Sehnert
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80355673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023002024(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2023002024A publication Critical patent/MX2023002024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
MX2023002024A 2020-08-28 2021-08-26 Métodos de tratamiento con modulador de miosina. MX2023002024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072094P 2020-08-28 2020-08-28
PCT/US2021/047711 WO2022047004A1 (en) 2020-08-28 2021-08-26 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
MX2023002024A true MX2023002024A (es) 2023-05-10

Family

ID=80355673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002024A MX2023002024A (es) 2020-08-28 2021-08-26 Métodos de tratamiento con modulador de miosina.

Country Status (10)

Country Link
US (1) US12616697B2 (enExample)
EP (1) EP4203927A4 (enExample)
JP (1) JP2023540485A (enExample)
KR (1) KR20230079053A (enExample)
CN (1) CN116490185A (enExample)
AU (1) AU2021334316A1 (enExample)
CA (1) CA3190060A1 (enExample)
IL (1) IL300775A (enExample)
MX (1) MX2023002024A (enExample)
WO (1) WO2022047004A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
US11488702B2 (en) 2019-07-18 2022-11-01 Physiq, Inc. System and method for improving cardiovascular health of humans
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2023133163A1 (en) 2022-01-05 2023-07-13 Prolaio, Inc. System and method for monitoring an efficacy of a treatment for a cardiac condition
CN119789856A (zh) * 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
EP4604841A1 (en) * 2022-10-21 2025-08-27 Prolaio, Inc. System and method of treatment of hypertrophic cardiomyopathy
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
IL322175A (en) * 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) * 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
WO2020151605A1 (zh) 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
WO2020165247A1 (de) 2019-02-12 2020-08-20 Basf Polyurethanes Gmbh Stossdämpferanordnung für eine fahrzeugfederung, und verwendung eines gleitmittels für selbige
WO2020257609A1 (en) 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
CA3157629A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator

Also Published As

Publication number Publication date
KR20230079053A (ko) 2023-06-05
EP4203927A4 (en) 2024-09-04
AU2021334316A9 (en) 2024-08-01
CA3190060A1 (en) 2022-03-03
WO2022047004A1 (en) 2022-03-03
CN116490185A (zh) 2023-07-25
IL300775A (en) 2023-04-01
AU2021334316A1 (en) 2023-05-04
EP4203927A1 (en) 2023-07-05
US12616697B2 (en) 2026-05-05
JP2023540485A (ja) 2023-09-25
US20240299390A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
MX2022000143A (es) Metodos novedosos.
CL2022001217A1 (es) Métodos de tratamiento con modulador de la miosina
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2022006208A (es) Metodos de tratamiento del cancer de pulmon de celulas peque?as con formulaciones de lurbinectedina.
MX2021005876A (es) Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
AR123227A1 (es) Terapias combinadas para su uso en el tratamiento del cáncer
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
CL2021002735A1 (es) Anticuerpos anti-pd-l1 modificados y métodos y usos para el tratamiento de una enfermedad neurodegenerativa
AR111491A1 (es) Métodos para tratar enfermedades pediátricas
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
CL2024003237A1 (es) Métodos de administración de inhibidores de miosina
MX2021009384A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2022004910A (es) Metodos de tratamiento de los sintomas del trastorno del espectro autista.
CL2022002423A1 (es) Métodos para tratar la enfermedad de fabry